Pharvaris N.V. PHVS

Pharvaris (NasdaqGS:PHVS) reported positive topline data from its CHAPTER-3 pivotal Phase 3 trial of deucrictibant XR for hereditary angioedema prevention. The study met all primary and secondary endpoints with statistical significance, supporting deucrictibant XR as a potential prophylactic treatment option. Management plans to use CHAPTER-3 data in upcoming marketing authorization applications for deucrictibant XR in hereditary angioedema. The statistically significant CHAPTER-3 outcome...

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said

Pharvaris N.V. (NASDAQ:PHVS) reported on September 8 that once-daily deucrictibant extended-release tablets reduced hereditary angioedema attack rates by 83% relative to placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a 95% confidence interval of 72% to 90% and a p-value below 0.0001. The global, double-blind study randomized 85 participants to […]

RBC Capital said it expects revenue tailwinds for BioCryst’s Orladeyo drug after Pharvaris posted strong Phase 3 data for HAE therapy.

BioCryst Pharmaceuticals' (BCRX) Ordaleyo faces competitive pressure in the hereditary angioedema tr

Pharvaris (PHVS) could gain greater market share in hereditary angioedema with its deucrictibant ext

The company will seek approval for deucrictibant XR as competition in the HAE market mounts.

Pharvaris said on Tuesday its once-daily experimental pill cut monthly swelling attacks by 83% versus a dummy treatment in a late-stage study of hereditary angioedema patients.

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus

Pharvaris (NASDAQ:PHVS) shares jumped 27% on Tuesday after the company reported positive topline results from its pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant XR for the prevention of hereditary angioedema attacks. The study met its primary endpoint, with once-daily deucrictibant XR producing an 83% reduction in the HAE attack rate compared with placebo.

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2All secondary efficacy endpoints met with statistical significanceWell-tolerated safety profile of deucrictibant XR demonstratedConference call and webcast today at 8:00 a.m. EDT ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-sta